BT Slingsby
Fondatore presso MINERALYS THERAPEUTICS, INC.
Posizioni attive di BT Slingsby
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Presidente | 31/05/2019 | - |
| Fondatore | 31/05/2019 | - | |
| Independent Dir/Board Member | 31/05/2019 | - | |
Kirilys Therapeutics, Inc.
 Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Amministratore Delegato | - | - |
| Presidente | - | - | |
| Fondatore | - | - | |
Pathalys Pharma, Inc.
 Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Presidente | - | - |
| Fondatore | - | - |
Storia della carriera di BT Slingsby
Formazione di BT Slingsby
| Kyoto University | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
| Giappone | 2 |
Posizioni
| Chairman | 3 |
| Founder | 3 |
| Independent Dir/Board Member | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
| Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Health Technology |
Kirilys Therapeutics, Inc.
Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Health Services |
- Borsa valori
- Insiders
- BT Slingsby
- Esperienza
